The neurotransmitter acetylcholine mediates a variety of responses within the central nervous system and plays an important role in memory function and cognition. Cholinergic cells within the basal forebrain denerate in Alzheimer's disease, a disorder associated with memory dysfunction and progressive cognitive decline. Research efforts have focused on developing selective M1 muscarinic agonists for the treatment of Alzheimer's disease. Over the past few years, several putative M1 agonists have been identified. The proposal focuses on the design, synthesis, and biological testing of novel compounds as selective muscarinic ligands. Chemical synthesis focuses on exploring a radically new approach to the development of muscarinic agonists, based on a novel series of bis-thiadiazole derivatives that display very high potency and activity at M1 receptors. Structure activity and molecular modeling studies will help identify the molecular features that contribute to activity and provide a basis for the rational design and synthesis of new ligands. In addition to pharmacological characterization of new compounds, biological studies will compare the affinity and efficiacy of several putative slective M1 muscarinic agonists at muscarinic receptors expressed in cultured cell lines and in the brain. Further studies will examine the ability of a few active and slective compounds to penetrate into the brain and reverse memory deficits associated with lesions of the septohippocampal cholinergic system. The overall goals of the project are to identify ligands with improved selectivity for muscarinic receptor subtypes, thereby providing important new pharmacological tools. A compound with high M1 agonists activity and the ability to penetrate into the brain also could become a drug candidate for the treatment of Alzheimer's disease. These studies will help determine the therapeutic utility of selective muscarinic agonists in the treatment of Alzheimer's disease. In addition the research could provide new approaches to the synthesis of compounds useful in a variety of neurological disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS031173-04A3
Application #
2904490
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Murphy, Diane
Project Start
1994-08-08
Project End
2003-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Toledo
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Toledo
State
OH
Country
United States
Zip Code
43606
Nagy, Peter I; Messer, William S (2011) Theoretical studies of the in-solution isomeric protonation of non-aromatic six-member rings with two nitrogens. J Phys Chem B 115:4758-67
Dokas, Linda A; Malone, Amy M; Williams, Frederick E et al. (2011) Multiple protein kinases determine the phosphorylated state of the small heat shock protein, HSP27, in SH-SY5Y neuroblastoma cells. Neuropharmacology 61:12-24
Nagy, Peter I; Maheshwari, Aditya; Kim, Yong-Wah et al. (2010) Theoretical and experimental studies of the isomeric protonation in solution for a prototype aliphatic ring containing two nitrogens. J Phys Chem B 114:349-60
Tejada, Frederick R; Nagy, Peter I; Xu, Min et al. (2006) Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the bind J Med Chem 49:7518-31
Nagy, Peter I; Tejada, Frederick R; Messer Jr, William S (2005) Theoretical studies of the tautomeric equilibria for five-member N-heterocycles in the gas phase and in solution. J Phys Chem B 109:22588-602
Cao, Yang; Zhang, Minjia; Wu, Cindy et al. (2003) Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. J Med Chem 46:4273-86
Messer Jr, William S (2002) The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 19:187-93
Rajeswaran, W G; Cao, Y; Huang, X P et al. (2001) Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J Med Chem 44:4563-76
Messer Jr, W S; Rajeswaran, W G; Cao, Y et al. (2000) Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv 74:135-40
Huang, X P; Williams, F E; Peseckis, S M et al. (1999) Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors. Mol Pharmacol 56:775-83

Showing the most recent 10 out of 13 publications